EPYGENIX THERAPEUTICS
Epygenix Therapeutics is a precision medicine-based biopharmaceutical company focused on discovering and developing drugs that treat Dravet syndrome (DS) and other genetic epilepsies. DS is a rare and catastrophic form of intractable epilepsy that begins in infancy. Current therapeutic options are not effective, and the constant care required can severely impact quality of life for the entire family. Dravet syndrome, like most genetic forms of epilepsy, represents an orphan indication with an unmet medical need.
EPYGENIX THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Address:
Paramus, New Jersey, United States
Country:
United States
Website Url:
http://www.epygenix.com
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Mobile Non Scaleable Content Sitelinks Search Box Organization Schema
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Current Employees Featured
Key Employee Changes
Official Site Inspections
http://www.epygenix.com Semrush global rank: 3.86 M Semrush visits lastest month: 3.38 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "EpyGenix Therapeutics"
EpyGenix Therapeutics - Crunchbase Company Profile & Funding
Epygenix Therapeutics is a precision medicine-based biopharmaceutical company focused on discovering and developing drugs that treat Dravet syndrome (DS) and other genetic …See details»
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding …
Apr 30, 2024 Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations. EPX-100 in Pivotal Registrational Trial for Dravet Syndrome; Topline Data …See details»
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding …
Apr 30, 2024 Harmony Biosciences (Nasdaq: HRMY), today announced the acquisition of Epygenix Therapeutics, Inc., accelerating its growth strategy by adding a rare epilepsy …See details»
Epygenix Therapeutics, Inc. | LinkedIn
Epygenix Therapeutics is a precision medicine-based biopharmaceutical company focused on discovering and developing drugs that treat Dravet syndrome (DS) and other genetic epilepsies.See details»
Epygenix Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Rare Epilepsy Acquired Epygenix Therapeutics, Inc., and establishes rare epilepsy franchise.Lead product, clemizole hydrochloride (EPX-100), is a potent, oral, centrally acting serotonin (5HT2) …See details»
Harmony Biosciences Acquires Epygenix Therapeutics, Inc
Apr 30, 2024 Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets Provided by PR Newswire …See details»
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding …
Harmony Biosciences announced the acquisition of Epygenix Therapeutics, Inc., accelerating its growth strategy by adding a rare epilepsy franchise to its expanding late-stage pipeline of …See details»
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding …
Apr 30, 2024 “The acquisition of Epygenix gives us three distinct CNS franchises in late-stage development, each with a potential US peak sales opportunity of $1B – $2B,” said Jeffrey M. …See details»
Harmony buys Epygenix for $35M upfront - Fierce Biotech
Apr 30, 2024 Harmony's stock soared after sporting solid revenue growth and buying Epygenix. Harmony Biosciences is adding a suite of epilepsy assets to its pipeline, buying Epygenix for …See details»
Harmony Biosciences (HRMY) Acquires Epygenix Therapeutics, Inc.
Apr 30, 2024 Harmony Biosciences (Nasdaq: HRMY), today announced the acquisition of Epygenix Therapeutics, Inc., accelerating its growth strategy by adding a rare epilepsy …See details»
Epygenix Therapeutics Announces Appointment of Darren Cline as …
Mar 15, 2022 new CEO's photo new CEO's photo PARAMUS, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company …See details»
Taking a patient-first, precision medicine approach to orphan drug ...
Epygenix Therapeutics, Inc. www.epygenix.com Taking a patient-first, precision medicine approach to orphan drug development Epygenix Therapeutics is a precision medicine bio -See details»
Epygenix Therapeutics Receives FDA Orphan Drug Designation for …
Jun 29, 2022 Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical company focused on genetically screening, discovering and developing drugs to treat rare and …See details»
Taking a patient-first, precision medicine approach to orphan drug ...
Epygenix expects to file an IND for a phase 1/2 trial of EPX-100 in the first quarter of 2018, setting it on a path that hopefully will lead to approval through the 505(b)(2) pathway.Epygenix’s ...See details»
Journey from Aquarium-to-Bedside to Treat Genetic Epilepsies
May 3, 2021 To move EPX drug candidates to the market in a timely manner, Epygenix is now rolling out a multi-national and multi-center clinical trial of EPX-100 as adjunctive therapy in …See details»
Epygenix Therapeutics Announces Appointment of G. Michael …
Mar 23, 2022 Featured Image for Epygenix Therapeutics, Inc. PARAMUS, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company …See details»
Epygenix Therapeutics Receives U.S. FDA Orphan Drug …
Aug 2, 2021 Epygenix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing drugs to treat rare and intractable genetic epilepsy. Epygenix is currently …See details»
FDA Accepts Epygenix Therapeutics IND to Initiate a Clinical Trial
Sep 1, 2021 Epygenix Therapeutics, Inc. ("Epygenix"), a clinical-stage biopharmaceutical company focused on rare and intractable genetic epilepsy, announced today that the U.S. …See details»
First Canadian Participant Dosed in ARGUS Trial, A Phase 2
Jun 1, 2022 Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical company focused on genetically screening, discovering and developing drugs to treat rare and …See details»
Epygenix Therapeutics Announces FDA Acceptance of IND to …
Aug 30, 2021 Epygenix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing drugs to treat rare and intractable genetic epilepsy. Epygenix is …See details»